HAART receipt and viral suppression among HIV-infected patients with co-occurring mental illness and illicit drug use

AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV

Volumn 21, Issue 5, 2009, Pages 655-663

  Chander, Geetanjali ^a   Himelhoch, Seth ^b   Fleishman, John A ^c   Hellinger, James ^d   Gaist, Paul ^e   Moore, Richard D ^a   Gebo, Kelly A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

^d TUFTS MEDICAL CENTER   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

HIV; Illicit drug use; Mental health; Viral suppression

Indexed keywords

ANTIRETROVIRUS AGENT; ILLICIT DRUG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COMORBIDITY; CONTROLLED STUDY; DRUG ABUSE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL HEALTH; OUTCOMES RESEARCH; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS INHIBITION; ADDICTION; ADOLESCENT; AGED; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; METABOLISM; MIDDLE AGED; MULTICENTER STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; COMORBIDITY; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; RNA, VIRAL; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 70349766072     PISSN: 09540121     EISSN: 13600451     Source Type: Journal    
DOI: 10.1080/09540120802459762     Document Type: Article

References (32)

1. Akincigil, A., Bowblis, J.R., Levin, C., Walkup, J.T., Jan, S., & Crystal, S. (2007). Adherence to antidepressant treatment among privately insured patients diagnosed with depression. Medical Care, 45, 363-369.
2. Anastos, K., Schneider, M.F., Gange, S.J., Minkoff, H., Greenblatt, R.M., Feldman, J., et al. (2005). The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women. Journal of Acquired Immune Deficiency Syndromes, 39, 537-544.
3. Brunette, M.F., & Mueser, K.T. (2006). Psychosocial interventions for the long-term management of patients with severe mental illness and co-occurring substance use disorder. Journal of Clinical Psychiatry, 67(Suppl. 7), 10-17.
4. Buckley, P.F. (2006). Prevalence and consequences of the dual diagnosis of substance abuse and severe mental illness. Journal of Clinical Psychiatry, 67(Suppl. 7), 5-9.
5. Compton, M.T., Weiss, P.S., West, J.C., & Kaslow, N.J. (2005). The associations between substance use disorders, schizophrenia-spectrum disorders, and Axis IV psychosocial problems. Social Psychiatry and Psychiatric Epidemiology, 40, 939-946.
6. Cook, J.A., Grey, D.D., Burke-Miller, J.K., Cohen, M.H., Vlahov, D., Kapadia, F., et al. (2007). Illicit drug use, depression and their association with highly active antiretroviral therapy in HIV-positive women. Drug Alcohol Depend, 89, 74-81.
7. Cournos, F., & McKirnan, D.J. (1997). Substance use and HIV risk among people with severe mental illness. 110- 129. 8-1-2007. Ref Type: Serial (Book, Monograph).
8. Drake, R. E., & Wallach, M.A. (1989). Substance abuse among the chronic mentally ill. Hospital & Community Psychiatry, 40, 1041-1046.
9. Galvan, F.H., Burnam, M.A., & Bing, E.G. (2003). Cooccurring psychiatric symptoms and drug dependence or heavy drinking among HIV-positive people. Journal of Psychoactive Drugs, 35(Suppl. 1), 153-160.
10. Gebo, K.A., Fleishman, J.A., Conviser, R., Reilly, E.D., Korthuis, P.T., Moore, R.D., et al. (2005). Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. Journal of Acquired Immune Deficiency Syndrome, 38, 96-103.
11. Gebo, K.A., Fleishman, J.A., Reilly, E.D., & Moore, R.D. (2005). High rates of primary Mycobacterium avium complex and Pneumocystis jiroveci prophylaxis in the United States. Medical Care, 43, III23-III30.
12. Himelhoch, S., Chander, G., Fleishman, J.A., Hellinger, J., Gaist, P., & Gebo, K.A. (2007). Access to HAART and utilization of inpatient medical hospital services among HIV-infected patients with co-occurring serious mental illness and injection drug use. General Hospital Psychiatry, 29, 518-525.
13. Hurlburt, M.S., Hough, R.L., & Wood, P.A. (1996). Effects of substance abuse on housing stability of homeless mentally Ill persons in supported housing. Psychiatric Services, 47, 731-736.
14. Kessler, R.C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K.R., et al. (2003). The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R). JAMA, 289, 3095-3105.
15. Li, X., Margolick, J.B., Conover, C.S., Badri, S., Riddler, S.A., Witt, M.D., et al. (2005). Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study. Journal of Acquired Immune Deficiency Syndromes, 38, 320-328. (Pubitemid 40333499)
16. Lucas, G.M., Gebo, K.A., Chaisson, R.E., & Moore, R.D. (2002). Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS, 16, 767-774.
17. Olfson, M., Mechanic, D., Hansell, S., Boyer, C.A., Walkup, J., & Weiden, P.J. (2000). Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatric Services, 51, 216-222.
18. Palepu, A., Tyndall, M., Yip, B., O'Shaughnessy, M.V., Hogg, R.S., & Montaner, J.S. (2003). Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use. Journal of Acquired Immune Deficiency Syndromes, 32, 522-526.
19. DHHS. (2006). Panel on antiretroviral guidelines for adult and adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services [On-line]. Retrieved February 2, 2008, from http://aidsinfo.nih. gov/Guidelines/ GuidelineDetail.aspx?MenuItem-Guide lines&Search-Off&GuidelineID- 7&ClassID-1.
20. Parienti, J.J., Massari, V., Descamps, D., Vabret, A., Bouvet, E., Larouze, B., et al. (2004). Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. Clinical Infectious Diseases, 38, 1311-1316.
21. Pence, B.W., Miller, W.C., Gaynes, B.N., & Eron, J.J., Jr. (2007). Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndrome, 44, 159-166.
22. RachBeisel, J., Scott, J., & Dixon, L. (1999). Co-occurring severe mental illness and substance use disorders: A review of recent research. Psychiatric Services, 50, 1427-1434.
23. Regier, D.A., Farmer, M.E., Rae, D.S., Locke, B.Z., Keith, S.J., Judd, L.L., et al. (1990). Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA, 264, 2511-2518.
24. Soto, T.A., Bell, J., & Pillen, M.B. (2004). Literature on integrated HIV care: A review. AIDS Care, 16(Suppl. 1), S43-S55.
25. Spire, B., Duran, S., Souville, M., Leport, C., Raffi, F., & Moatti, J.P. (2002). Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: From a predictive to a dynamic approach. Social Science Medicine, 54, 1481-1496.
26. Substance Abuse and Mental Health Services Administration (SAMHSA). (2004). Results from the 2003 national survey on drug use and health: National findings. (Office of Applied Studies, NSDUH Series H-25, DHHS Publication No.SMA 04-3964) [On-line]. Retrieved from http://www.oas.samhsa.gov/nhsda/2k3nsduh/ 2k3results.htm#8.1
27. Turner, B.J., Fleishman, J.A., Wenger, N., London, A.S., Burnam, M.A., Shapiro, M.F., et al. (2001). Effects of drug abuse and mental disorders on use and type of antiretroviral therapy in HIV-infected persons. Journal of General Internal Medicine, 16, 625-633.
28. Watkins, K.E., Paddock, S.M., Zhang, L., & Wells, K.B. (2006). Improving care for depression in patients with comorbid substance misuse. American Journal of Psychiatry, 163, 125-132.
29. Wilk, J., Marcus, S.C., West, J., Countis, L., Hall, R., Regier, D. A., et al. (2006). Substance abuse and the management of medication nonadherence in schizophrenia. Journal of Nervous and Mental Disease, 194, 454-457.
30. Wood, E., Kerr, T., Tyndall, M.W., & Montaner, J.S. (2008). A review of barriers and facilitators of HIV treatment among injection drug users. AIDS, 22, 1247-1256.
31. Wood, E., Montaner, J.S., Yip, B., Tyndall, M.W., Schechter, M.T., O'Shaughnessy, M.V., et al. (2003). Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ, 169, 656-661.
32. Wood, E., Montaner, J.S., Yip, B., Tyndall, M.W., Schechter, M.T., O'Shaughnessy, M.V., et al. (2004). Adherence to antiretroviral therapy and CD4 T-cell count responses among HIV-infected injection drug users. Antiviral Therapy, 9, 229-235. (Pubitemid 38560216)